On-Body Infusor System for Repatha to Be Discontinued Soon

Amgen has announced that the Repatha (evolocumab) Pushtronix^® System (single-dose on-body infusor with prefilled cartridge) will be discontinued. 

Repatha, a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, is indicated as adjunctive therapy to reduce low-density lipoprotein cholesterol (LDL-C): in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH); in pediatric patients aged 10 years and older with HeFH; and in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. It is also approved to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.

According to the Company, the decision to discontinue the Repatha Pushtronex System was not due to the product’s quality, efficacy or safety. The Repatha Pushtronex System will be discontinued as of June 30, 2024. 

Patients continuing with Repatha treatment should be transitioned to either the single-dose prefilled syringe (140 mg/mL) or the single-dose prefilled SureClick^® autoinjector (140 mg/mL).

Each single-dose Pushtronex system delivers a 3.5 mL solution containing 420 mg of evolocumab. With this discontinuation, the 420 mg dose of Repatha can be administered by giving 3 injections consecutively within 30 minutes using the single-dose prefilled autoinjector or single-dose prefilled syringe.

This article originally appeared on MPR